SEAS 2008

NCT00092677

1 Treatments

Studied treatment  simvastatin 40mg plus ezetimibe 10 mg daily

Control treatment  placebo

Concomitant treatments  -

2 Patients

Patients  patients with mild-to-moderate, asymptomatic aortic stenosis

Inclusion criteria  men and women; between the ages of 45 and 85 years; asymptomatic, mild-to-moderate aortic valve stenosis with a peak aortic-jet velocity of 2.5 to 4 m per second on echocardiography

Exclusion criteria  symptoms of coronary artery disease, peripheral arterial disease, cerebrovascular disease, diabetes mellitus or any other condition requiring lipid-lowering therapy

3 Methods

Blinding  double blind

Design  Parallel groups

Centers  173

Geographical area  Europe

Sizes  944/929

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>CV death</td>
<td>47/944</td>
<td>56/929</td>
<td>0,83</td>
<td>[0,55; 1,23]</td>
</tr>
<tr>
<td>Hospitalization for severe aortic stenosis</td>
<td>-/944</td>
<td>-/929</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Death from any cause</td>
<td>105/944</td>
<td>100/929</td>
<td>1,03</td>
<td>[0,77; 1,38]</td>
</tr>
<tr>
<td>CV death, aortic replacement, hospitalization for severe aortic stenosis</td>
<td>333/944</td>
<td>355/929</td>
<td>0,92</td>
<td>[0,76; 1,05]</td>
</tr>
<tr>
<td>Aortic-valve replacement</td>
<td>267/944</td>
<td>278/929</td>
<td>0,95</td>
<td>[0,77; 1,13]</td>
</tr>
</tbody>
</table>
5 References